Novo Nordisk's next-gen obesity drug CagriSema trial results disappoint investors US$ 24.50 Min. order: 1 piece ★★★★★ 4.5 (281 reviews) Sold : Login>>
Novo Nordisk Offers New Contender in Weight Management US$ 26.12 Min. order: 1 piece ★★★★★ 4.6 (256 reviews) Sold : Login>>
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial US$ 22.52 Min. order: 1 piece ★★★★★ 4.8 (252 reviews) Sold : Login>>
Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues US$ 23.01 Min. order: 1 piece ★★★★★ 4.4 (137 reviews) Sold : Login>>
Based on the early promising data for injectable cagrilintide-semaglutide combination for #obesity #T2D @novonordisk move to test an oral GLP-1 Amylin Amycretin peptide in healthy PPL with overweight and #obesity in P1 US$ 25.36 Min. order: 1 piece ★★★★★ 4.7 (240 reviews) Sold : Login>>